Pharma/Biotech Analyst

I am a graduate of  Industrial and Business Service Management and have created my own Pharmaceutical website "BiotechPicklist.com." I have been investing and writing about biotechnology stocks for many years now and have extensive experience writing about the science and ... more

ALL CONTRIBUTIONS

E Matinas Biopharma Is Highly Undervalued
With cash concerns put to rest, a solid lead product MAT9001, and a unique lipid nano-crystal delivery technology, I believe Matinas Biopharma is highly undervalued.
Read
E Bellicum Is Worth A Look With Multiple Catalysts On The Way In 2nd Half Of 2019
Bellicum is a highly undervalued biotech. Especially, when you consider that it has two types of technology that can be utilized to potentially alter how CAR-T therapies are produced.
Read
E Finally A Real Cancer Diagnosis Breakthrough?
TOMDF is a diagnostics company that utilizes blood tests for early detection of cancer and neurodegenerative diseases. But is it a good investment? I took a deeper look and reached out to the company's CEO, Herman Weiss, to get the facts.
Read
E Rexahn's Deal With China For RX-3117 Candidate Moves It Back On The Right Track
Rexahn Pharma generates a deal in Greater China for its clinical cancer product. Here's what you need to know...
Read
E CVR Medical: A New Approach To Cardiovascular Care
CVR Medical's proprietary device could change the spectrum of stroke prevention and diagnostics.
Read
E VistaGen Therapeutics: Interesting Prospects
VistaGen's drug AV-101 has breakthrough potential for treatment of depression and other indications.
Read

Comments

Latest Comments
Bellicum Is Worth A Look With Multiple Catalysts On The Way In 2nd Half Of 2019
8 days ago

That's hard to say because it depends on negotiations. But Rivo-cel in Europe in pediatric setting can garner $500 million to $700 million in revenue. On top of the phase 2/3 THRIVE study which is ongoing right now, once data for that is revealed if it is successful with primary endpoint that adult population would add the potential for $3 to $4 billion in revenue. So on that basis I would say a very good chance. Having said that it's hard to say when it will come. Because big deals take about 3 to 6 months to negotiate. So without knowing when they started talks it's hard to say exactly.

In this article: BLCM
Bellicum Is Worth A Look With Multiple Catalysts On The Way In 2nd Half Of 2019
11 days ago

That's because before the recent influx of cash investors were worried about dilution or cash raise. They knew that cash was low and they were going to need more cash. So any catalyst of course would have cause new lows. However, now with Baker Brothers and financing completed they have cash slightly past 2021. They are good on cash now. I don't believe any positive catalyst will have a negative reaction. Also, it depends. If Bellicum finds a partner for instance for Europe on rivo-cel with upfront cash and milestone payments it will trade higher. But thanks for your opinion.

In this article: BLCM
Finally A Real Cancer Diagnosis Breakthrough?
4 months ago

Well right now the company is starting to commercialize so it wont' be like instant gratification. But as long as tests can be approved in multiple territories it will get better.

In this article: TOMDF, AMBS
Finally A Real Cancer Diagnosis Breakthrough?
4 months ago

Sorry for your Mother, yes such earlier detection will be needed in the future to save more lives.

In this article: TOMDF, AMBS
Finally A Real Cancer Diagnosis Breakthrough?
4 months ago

Basically, instead of waiting to detect the cancer itself when its just about late in the game, it detects how the immune system reacts to the cancer. This leads to a much earlier diagnosis.

In this article: TOMDF, AMBS
Finally A Real Cancer Diagnosis Breakthrough?
4 months ago

bottom line the way the test works it can detect disease at an earlier stage of the process. This helps with both the patient being treated earlier and at a cheaper cost.

In this article: TOMDF, AMBS
Finally A Real Cancer Diagnosis Breakthrough?
4 months ago

That's because big pharma companies have a better shot at succeeding in clinical trials. The failure rate for developing drugs to treat Alzheimer's is low, but the problem is acquisition costs of patients and recruit patients who definitely have the disease. Also as Herman says to get an earlier diagnosis would mean that someone with Alzheimer's stands a better shot at being treated.

In this article: TOMDF, AMBS
Finally A Real Cancer Diagnosis Breakthrough?
4 months ago

Yes the science of it is quite interesting.

In this article: TOMDF, AMBS
Finally A Real Cancer Diagnosis Breakthrough?
4 months ago

basically it's a cheaper blood test and it can detect cancer at an earlier stage than other tests. That's because it doesn't look at detecting cancer itself, it detects how your immune system reacts to the cancer.

In this article: TOMDF, AMBS
Finally A Real Cancer Diagnosis Breakthrough?
4 months ago

yes good for both investors and for shareholders of the company. Will start to improve as more territories are commercialized.

In this article: TOMDF, AMBS
1 to 10 of 81 comments
1 2 3 ... 9

STOCKS I FOLLOW

ARWR Arrowhead Research Corporation
CLDX Celldex Therapeutics Inc
EPZM Epizyme
INO Inovio Pharmaceuticals, Inc.
ONCS ONCOSEC MEDICAL
RNN Rexahn Pharmaceuticals Inc
RXII RXi Pharmaceuticals Corporation
SGMO Sangamo BioSciences Inc.
TKMR Tekmira Pharmaceuticals Corp

TWEETS

LATEST ACTIVITY

Terry Chrisomalis Commented on Bellicum Is Worth A Look With Multiple Catalysts On The Way In 2nd Half Of 2019:

That's hard to say because it depends on negotiations. But Rivo-cel in Europe in pediatric setting can garner $500 million to $700 million in revenue. On top of the phase 2/3 THRIVE study which is ongoing...

more
Terry Chrisomalis Commented on Bellicum Is Worth A Look With Multiple Catalysts On The Way In 2nd Half Of 2019:

That's because before the recent influx of cash investors were worried about dilution or cash raise. They knew that cash was low and they were going to need more cash. So any catalyst of course would hav...

more
All Posts

PERSONAL BLOG

Latest Posts

Work Experience

Contributor
Modest Money
January 2016 - Present (3 years 9 months)

Modest Money Contributor

Contributor
AnyOptionsBlogTM
March 2016 - Present (3 years 7 months)
Contributor
AOMarkets
November 2015 - Present (3 years 11 months)
CNA Finance
CNA Finance Contributor
February 2015 - Present (4 years 8 months)
CNA Finance Columnist
Wallstreetrain
Wallstreerain.com
March 2015 - Present (4 years 7 months)

Founder of Wallstreetrain.com

TalkMarkets Contributor
TalkMarkets
May 2014 - Present (5 years 5 months)
http://www.talkmarkets.com/contributor/Terry-Chrisomalis/
Founder
BiotechPickList
August 2013 - Present (6 years 3 months)
Run a Biotechnology Website/Pharmaceutical News
Seeking Alpha Contributor
Seeking Alpha
January 2013 - Present (6 years 10 months)
Biotechnology/Healthcare Articles for Seeking Alpha
Motley Fool Contributor
Motley Fool
January 2012 - August 2013 (1 year 8 months)

Education

St. Petersburg College
Bachelors of Business Administration
2004 / 2008
Business

Publications